Search
  • sr0213

Promethean BioPharma supports the rescheduling of psilocybin and MDMA in Australia

Updated: Mar 8

Promethean BioPharma supports the work of Mind Medicine Australia and encourages their submissions to the Therapeutic Goods Administration in relation to the rescheduling of psilocybin and MDMA from Schedule 9 to Schedule 8.


For more information:

https://mindmedicineaustralia.org.au/


https://mindmedicineaustralia.org.au/wp-content/uploads/Mind-Medicine-Australia-Invitation-for-Rescheduling-Guide-27-August-2020.pdf


https://mindmedicineaustralia.org.au/wp-content/uploads/Mind-Medicine-Australia-Fact-Sheet-22-February-2021.pdf


Recent Posts

See All

Promethean BioPharma Limited has finalised the acquisition of Tcann Pty Ltd setting the stage for the execution of it's growth strategy.